Diverse metrics of tumor immune infiltration including the amount of CD8+ cytotoxic T-cells or RNA signatures of T-effector cells have been linked with clinical benefit to CTLA-4 and PD-1 axis blockers1,11,12,17,31. The gene discussed is PDCD1; the disease is neoplasm.